Cargando…

Search for new α1a-adrenoceptor-selective antagonist for treating lower urinary tract symptoms associated with benign prostatic hyperplasia

Detalles Bibliográficos
Autores principales:	Khurana, Naval, Srivastava, Aneesh
Formato:	Texto
Lenguaje:	English
Publicado:	Medknow Publications 2007
Materias:	Uroscan
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2721542/ https://www.ncbi.nlm.nih.gov/pubmed/19675810

Ejemplares similares

Which one is better, Wallace or Bricker?
por: Khurana, Naval, et al.
Publicado: (2007)

Are we along the path for laparoscopic partial nephrectomy?
por: Khurana, Naval, et al.
Publicado: (2007)

Transurethral ethanol ablation for symptomatic benign prostatic hyperplasia
por: Gautam, Gagan, et al.
Publicado: (2007)

A novel approach to management of nocturia in patients with benign prostatic hyperplasia
por: Sengottayan, Vengetesh K., et al.
Publicado: (2009)

Intraprostatic injection of botulinum toxin A: A promising treatment for patients with benign prostatic hyperplasia
por: Agrawal, S. K., et al.
Publicado: (2009)

Vaginal mucosal vaccine for recurrent urinary tract infections
por: Gautam, Gagan, et al.
Publicado: (2007)

What is the role of adjuvant chemotherapy in locally advanced and lymph node-positive bladder cancer after radical cystectomy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

What happens to the patients with muscle-invasive bladder cancer who refuse cystectomy after neoadjuvant chemotherapy?
por: Maheshwari, Ruchir, et al.
Publicado: (2009)

Should small renal masses be managed expectantly?
por: Singla, Manish, et al.
Publicado: (2007)

Does treatment rate impact the efficacy of extracorporeal shock wave lithotripsy for kidney or ureteral stones?
por: Muruganandham, K., et al.
Publicado: (2007)

Ureteroilleal anastomosis in orthotopic ileal neobladders: Does technique matter?
por: Gupta, Parag, et al.
Publicado: (2008)

Nitrous oxide during anesthesia for laparoscopic donor nephrectomy: Does it matter?
por: Singh, Pratipal, et al.
Publicado: (2008)

A comparison of traditional anterior colporrhaphy, polypropylene mesh and porcine dermis in cystocele repair
por: Singh, Pratipal, et al.
Publicado: (2007)

Stress urinary incontinence: Sling or colposuspension?
por: Mukha, Rajiv Paul, et al.
Publicado: (2007)

Risk factors for persistent stress urinary incontinence after mid-urethral procedures
por: Chawla, Arun, et al.
Publicado: (2008)

The Potential Role of Urinary Microbiome in Benign Prostate Hyperplasia/Lower Urinary Tract Symptoms
por: Yu, Seong Hyeon, et al.
Publicado: (2022)

Is Increased Prostatic Urethral Angle Related to Lower Urinary Tract Symptoms in Males with Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms?
por: Park, Yoo Jun, et al.
Publicado: (2012)

POUT trial: Perioperative chemotherapy in upper tract urothelial carcinoma – A standard of care?
por: Ranjan, Satish Kumar
Publicado: (2020)

Defining the role of antioxidants in the prevention of prostate cancer
por: Pathak, Hemant R., et al.
Publicado: (2009)

Lutetium-177 prostate-specific membrane antigen-617 theranostics: New therapeutic hope in metastatic castrate-resistant prostate cancer?
por: Ranjan, Satish Kumar
Publicado: (2020)

Does antenatal pelvic floor muscle training prevent stress urinary incontinence in primi-gravidae?
por: Gupta, Gaurav, et al.
Publicado: (2009)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

The current role of Active Surveillance in early prostate cancer
por: Shrinivas, R. P., et al.
Publicado: (2009)

The predictive factors of α1-D/A adrenoceptor antagonist, naftopidil, dose increase therapy for male lower urinary tract symptoms caused by benign prostatic hyperplasia: INFORM study
por: Tanuma, Yasushi, et al.
Publicado: (2017)

Lower urinary tract symptoms and benign prostatic hyperplasia: From research to bedside
por: Goel, Apul
Publicado: (2019)

Safety and efficacy of active surveillance in patients with localized prostate cancer
por: Mavuduru, Ravimohan, et al.
Publicado: (2008)

Prostate cancer treatment does not increase the risk of cardiovascular events
por: Khochikar, Makarand V.
Publicado: (2007)

Relugolix – The novel oral androgen deprivation therapy for prostate cancer
por: Jena, Rahul
Publicado: (2020)

Rezvilutamide for metastatic castration-sensitive prostate cancer: CHART trial
por: Singh, Kirti
Publicado: (2023)

Is incidence of prostate cancer higher in patients with end stage renal disease?
por: Khochikar, Makarand V.
Publicado: (2007)

PROFOUND trial –a new era in targeted therapeutics for prostate carcinoma
por: Tosh, Jyoti Mohan
Publicado: (2022)

Apalutamide: A novel therapy for non metastatic castration-resistant carcinoma prostate
por: Jayasimha, Sudhindra
Publicado: (2018)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
por: Talwar, Harkirat Singh
Publicado: (2021)

Triple therapy for metastatic castration sensitive prostate cancer: PEACE-1 trial
por: Singh, Kirti
Publicado: (2022)

Seasonal Variation of Urinary Symptoms in Korean Men with Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia
por: Choi, Ho Chul, et al.
Publicado: (2015)

Survival following primary androgen deprivation therapy among men with localized prostate cancer
por: Vasudeva, Pawan, et al.
Publicado: (2008)

Thulium laser versus standard transurethral resection of the prostate: A randomized prospective trial
por: Dubey, Deepak, et al.
Publicado: (2008)

L.I.F.T. study: Prostatic urethral lift for the treatment of LUTS associated with BPH
por: Gupta, Saurabh
Publicado: (2014)

Multiparametric magnetic resonance imaging-targeted biopsies in the detection of clinically significant prostate cancer
por: Charalampos, Fragkoulis
Publicado: (2020)

TITAN trial; shifting focus from hormone-refractory to hormone-sensitive prostate cancer
por: Kumar, Gautam
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_p06me3hd06ep0o7if4t9hi760g